FDA Approved: SABRIL — Supplemental Application (Lundbeck Pharmaceuticals LLC)

View source ↗

Summary

The FDA approved Lundbeck's supplemental application for SABRIL (vigabatrin), updating the labeling per NDA020427. This approval reflects changes to indications…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy
• Infantile Spasms
• Partial Seizures

Drugs mentioned

• SABRIL (VIGABATRIN)

Snippet

SUPPL AP for SABRIL (VIGABATRIN)